Accelerated Evolution Of Prostate Cancer Therapy Shaped Xtandi Review

Medivation/Astellas’ enzalutamide capped off an extraordinary three-year run in advanced castration-resistant prostate cancer therapy, with three successive NMEs each offering a greater survival advantage than the last. That accelerated evolution of new therapies created a complex context for FDA reviews.